We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03551249
Recruitment Status : Active, not recruiting
First Posted : June 11, 2018
Last Update Posted : September 10, 2022
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2 used as a tool to disrupt the BBB (blood brain barrier) in patients with high grade glioma undergoing standard of care therapy.

Condition or disease Intervention/treatment Phase
Glioma Glioblastoma Device: Focused ultrasound (FUS) Not Applicable

Detailed Description:
This is a prospective, multi-center, single-arm study to establish the safety and feasibility of BBB (blood brain barrier) disruption along the periphery of tumor resection cavity using the ExAblate Neuro Model 4000 Type 2 (220 kHz) system. For this study, patients will be eligible to enroll in the study prior to beginning the planned adjuvant TMZ chemotherapy phase of treatment. Of note, only patients who are deemed eligible for adjuvant TMZ will be eligible for enrollment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier Disruption for the Treatment of High Grade Glioma in Patients Undergoing Standard Chemotherapy
Actual Study Start Date : March 26, 2019
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Focused Ultrasound (FUS)
The ExAblate Model 4000 Type 2 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing initial standard of care chemotherapy.
Device: Focused ultrasound (FUS)
FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.
Other Name: ExAblate, Type 2

Primary Outcome Measures :
  1. Device and procedure related adverse events [ Time Frame: Throughout the study, approximately 12 months. ]
    The number and severity of device and BBB disruption procedure related adverse events will be evaluated and classified according to the CTCAE

Secondary Outcome Measures :
  1. Feasibility of repeated BBB disruption will be evaluated through assessment of post-procedure contrast-enhanced magnetic resonance (MR) imaging [ Time Frame: At the time of each ExAblate MRgFUS procedure ]
    The repeatability of BBB disruption will be evaluated at each of the 6 procedures and will be evaluated through assessment of post-procedure contrast-enhanced MR imaging.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient is eligible for adjuvant temozolomide (TMZ) treatment based on the current standard of care.
  2. Men or women age between 18 and 80 years, inclusive.
  3. Able and willing to give informed consent.
  4. Grade IV glioma (GBM)
  5. Combined radiation/TMZ treatment is completed based on the prescribed standard of care regimen.
  6. Karnofsky rating 70-100.
  7. Able to communicate during the ExAblate BBBD (Blood Brain Barrier Disruption) procedure.
  8. Able to attend all study visits (i.e., life expectancy of at least 3 months).

Exclusion Criteria:

  1. Patients presenting with the following imaging characteristics:

    i. Evidence of acute intracranial hemorrhage.

  2. The sonication pathway to the tumor involves:

    i. Extensive scalp sores. ii. Clips or other metallic implanted objects in the skull or the brain (brain implants)

  3. The subject presents with symptoms and signs of increased intracranial pressure (e.g., headache, nausea, vomiting, lethargy, and papilledema).
  4. Patients with cerebellar or brainstem tumors.
  5. Patients with positive HIV status.
  6. Significant depression not adequately controlled with medication and at potential risk of suicide.
  7. Patient receiving bevacizumab (Avastin) therapy.
  8. Patients receiving treatment with corticosteroid doses greater than dexamethasone 24 mg daily (or equivalent).
  9. Patients undergoing other concurrent therapies such as chemotherapy wafers, immunotoxins delivered by convection-enhanced delivery, regionally administered gene and viral therapies, immunotherapies, focal irradiation with brachytherapy, stereotactic radiosurgery, laser interstitial thermotherapy, and tumor treatment fields therapy.
  10. Cardiac disease or unstable hemodynamics including:

    i. Documented myocardial infarction within six months of enrollment. ii. Unstable angina on medication. iii. Congestive heart failure. iv. Left ventricular ejection fraction <50%. v. History of a hemodynamically unstable cardiac arrhythmia. vi. Cardiac pacemaker.

  11. Severe hypertension (diastolic BP > 100 on medication).
  12. Anti-coagulant therapy, or medications known to increase risk of hemorrhage within washout period prior to treatment.
  13. History of a bleeding disorder, coagulopathy or with a history of spontaneous tumor hemorrhage.
  14. Cerebral or systemic vasculopathy, including intracranial thrombosis, vascular malformation, cerebral aneurysm or vasculitis.
  15. History of drug or alcohol use disorder.
  16. Active seizure disorder or epilepsy (seizures despite medical treatment).
  17. Known sensitivity to gadolinium-based contrast agents.
  18. Known sensitivity to DEFINITY® ultrasound contrast agent or perflutren.
  19. Contraindications to MRI such as non-MRI-compatible implanted devices.
  20. Large subjects not fitting comfortably into the MRI scanner.
  21. Difficulty lying supine and still for up to 4 hours in the MRI unit or claustrophobia.
  22. Positive pregnancy test (women of childbearing potential).
  23. Severely impaired renal function or on dialysis.
  24. Cardiac shunt.
  25. Subjects with evidence of cranial or systemic infection.
  26. Subjects with significant liver dysfunction, e.g., history of cirrhosis or active hepatitis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03551249

Layout table for location information
United States, Maryland
University of Maryland
Baltimore, Maryland, United States, 21201
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States, 22908
United States, West Virginia
West Virginia University
Morgantown, West Virginia, United States, 26506
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Graeme Woodworth, MD University of Maryland
Layout table for additonal information
Responsible Party: InSightec
ClinicalTrials.gov Identifier: NCT03551249    
Other Study ID Numbers: BT008
First Posted: June 11, 2018    Key Record Dates
Last Update Posted: September 10, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue